{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "VATC|IMMUNOSUPPRESSANTS|IMMUNOSUPPRESSANTS|Selective immunosuppressants" in comments (approximate match)
Status:
US Approved Rx
(2007)
Source:
BLA125166
(2007)
Source URL:
First approved in 2007
Source:
BLA125166
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2005)
Source:
BLA125118
(2005)
Source URL:
First approved in 2005
Source:
BLA125118
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2004)
Source:
BLA125104
(2004)
Source URL:
First approved in 2004
Source:
BLA125104
Source URL:
Class:
PROTEIN
Status:
US Previously Marketed
Source:
Raptiva
(2003)
Source URL:
First approved in 2003
Source:
Raptiva
Source URL:
Class:
PROTEIN
Status:
US Previously Marketed
Source:
Amevive
(2003)
Source URL:
First approved in 2003
Source:
Amevive
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 2007
Source:
21 CFR 352
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(1999)
First approved in 1998
Source:
BLA103869
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(1996)
First approved in 1981
Source:
BLA103676
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2019)
Source:
ANDA212453
(2019)
Source URL:
First approved in 1998
Source:
NDA020905
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Teriflunomide (trade name Aubagio, marketed by Sanofi) is the active metabolite of leflunomide and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis by blocking the enzyme dihydroorotate dehydrogenase. Teriflunomide was investigated in the Phase III clinical trial TEMSO as a medication for multiple sclerosis (MS). The drug was approved by the FDA on September 13, 2012 and in the European Union on August 26, 2013. It is uncertain whether this explains its effect on MS lesions. Teriflunomide inhibits rapidly dividing cells, including activated T cells, which are thought to drive the disease process in MS. Teriflunomide may decrease the risk of infections compared to chemotherapy-like drugs because of its more-limited effects on the immune system. It has been found that teriflunomide blocks the transcription factor NF-κB. It also inhibits tyrosine kinase enzymes, but only in high doses not clinically used.
